Drug Profile
Efanesoctocog alfa - Bioverativ/Sanofi
Alternative Names: Altuviiio; Antihemophilic factor (recombinant) - Bioverativ/Sanofi; BIVV-001; Factor VIII recombinant - Bioverativ/Sanofi; Fc-VWF-XTEN fusion protein-ehtl; Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion protein; rFVIIIFc-VWF-XTEN; rFVIIIFc-XTEN-vWF; XTENylated Factor VIIILatest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Amunix
- Developer Amunix; Bioverativ; Sanofi; Swedish Orphan Biovitrum
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant fusion proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A
- Phase I Von Willebrand disease
Most Recent Events
- 06 Mar 2024 Swedish Orphan Biovitrum and Syneos Health initiates a phase IIIb FREEDOM trial for Haemophilia A (Treatment experienced, In adolescents, In adults, In elderly) in Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Ireland, Netherlands, Norway, Slovenia, Spain, Sweden, United Kingdom (IV) (NCT05817812)
- 31 Dec 2023 Preregistration for Haemophilia A in Saudi Arabia (IV) prior to December 2023
- 31 Dec 2023 Launched for Haemophilia A (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in Japan (IV)